Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.95 +8.9%	$6.99	$3.54 ▼ $8.25	$148.63M	0.87	82,353 shs	113,882 shs
EOLS Evolus	$9.62 +2.6%	$10.24	$8.67 ▼ $17.82	$604.78M	1	748,735 shs	970,719 shs
KALV KalVista Pharmaceuticals	$11.70 -1.9%	$12.50	$7.30 ▼ $15.50	$593.11M	-0.01	481,536 shs	4.39 million shs
SANA Sana Biotechnology	$2.97 +14.2%	$2.12	$1.26 ▼ $7.40	$586.24M	1.78	3.66 million shs	5.76 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+8.93%	+10.14%	-0.71%	+13.19%	+40.97%
EOLS Evolus	+2.56%	+4.00%	-0.62%	-22.61%	-8.47%
KALV KalVista Pharmaceuticals	-1.93%	-3.70%	+2.01%	-3.07%	-0.17%
SANA Sana Biotechnology	+14.23%	+5.69%	+49.25%	+64.09%	-46.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	2.3959 of 5 stars	3.6	2.0	0.0	2.0	1.7	0.6
EOLS Evolus	3.8893 of 5 stars	3.5	1.0	3.5	1.7	3.3	0.6
KALV KalVista Pharmaceuticals	3.8458 of 5 stars	3.6	0.0	4.4	2.2	2.5	0.6
SANA Sana Biotechnology	2.5485 of 5 stars	3.4	0.0	0.0	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	3.20	Buy	$9.88	42.09% Upside
EOLS Evolus	3.00	Buy	$23.75	146.88% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	112.25% Upside
SANA Sana Biotechnology	3.00	Buy	$9.83	231.09% Upside

Current Analyst Ratings Breakdown

Latest DERM, KALV, EOLS, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
5/15/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/10/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/9/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/27/2025	DERM Journey Medical	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$10.50
3/27/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	2.88	N/A	N/A	$0.91 per share	7.64
EOLS Evolus	$266.27M	2.33	N/A	N/A	$0.09 per share	106.89
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	N/A	-14.76%	-52.03%	-11.28%	8/11/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest DERM, KALV, EOLS, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
3/26/2025	Q4 2024	DERM Journey Medical	-$0.22	$0.08	+$0.30	$0.08	$14.21 million	$14.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.07	1.34	1.03
EOLS Evolus	22.00	2.34	2.16
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
EOLS Evolus	90.69%
KALV KalVista Pharmaceuticals	N/A
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	15.03%
EOLS Evolus	6.10%
KALV KalVista Pharmaceuticals	10.50%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
EOLS Evolus	170	64.48 million	60.54 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable

DERM, KALV, EOLS, and SANA Headlines

Recent News About These Companies

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus Price Target from Brokerages

June 25 at 1:13 AM | americanbankingnews.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24 at 4:18 PM | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

June 24 at 9:54 AM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?

June 23 at 1:11 PM | marketbeat.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23 at 12:33 PM | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23 at 12:33 PM | benzinga.com

Sana Biotechnology Shares Climb on Positive Diabetes Study Results

June 23 at 12:33 PM | marketwatch.com

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

June 23 at 10:46 AM | quiverquant.com

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

June 23 at 10:05 AM | globenewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts

June 22 at 4:05 AM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Clarius Group LLC

June 20, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?

June 17, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine

June 7, 2025 | kalkinemedia.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LP

June 6, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLC

June 5, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 10.9% - Time to Buy?

June 4, 2025 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM, KALV, EOLS, and SANA Company Descriptions

Journey Medical NASDAQ:DERM

$6.95 +0.57 (+8.93%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$6.95 0.00 (0.00%)

As of 06/24/2025 06:46 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Evolus NASDAQ:EOLS

$9.62 +0.24 (+2.56%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$9.65 +0.03 (+0.31%)

As of 05:09 AM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

KalVista Pharmaceuticals NASDAQ:KALV

$11.70 -0.23 (-1.93%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$12.05 +0.35 (+2.99%)

As of 06:46 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$2.97 +0.37 (+14.23%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$2.98 +0.00 (+0.17%)

As of 06:45 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time